CliffBio
small molecule

ANGIOMAX RTU

BIVALIRUDIN

Loss of exclusivityMay 2039latest FDA-listed patent expiry
CompanyMaia →View the full company profile on CliffBio

Drug detail

Brand nameANGIOMAX RTU
Active ingredientBIVALIRUDIN
Strength250MG/50ML (5MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJuly 2019
Marketing statusRX

Listed patents

PatentExpiresType
11903993May 2039use U-3817
12472224May 2039product
11918622May 2039use U-3817
11992514May 2039product

More from Maia

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ANGIOMAX RTU patent cliff — loss of exclusivity May 2039 | CliffBio